WO1996037191A1 - Compositions antibacteriennes - Google Patents

Compositions antibacteriennes Download PDF

Info

Publication number
WO1996037191A1
WO1996037191A1 PCT/US1995/006587 US9506587W WO9637191A1 WO 1996037191 A1 WO1996037191 A1 WO 1996037191A1 US 9506587 W US9506587 W US 9506587W WO 9637191 A1 WO9637191 A1 WO 9637191A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ciprofloxacin
polystyrene sulfonic
concentration
compositions
Prior art date
Application number
PCT/US1995/006587
Other languages
English (en)
Inventor
Yusuf Ali
Rajni Jani
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to PCT/US1995/006587 priority Critical patent/WO1996037191A1/fr
Priority to AU27621/95A priority patent/AU705718B2/en
Priority to JP52719495A priority patent/JP2944759B2/ja
Publication of WO1996037191A1 publication Critical patent/WO1996037191A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Definitions

  • the present invention relates to pharmaceutical compositions comprising a synergistic combination of a quinolone, specifically ciprofloxacin, and a polystyrene sulfonic acid polymer.
  • Ciprofloxacin (CiloxanTM, Alcon Laboratories, Inc., Fort Worth, Texas, U.S.A.) is being used to treat ocular bacterial infections.
  • Ciprofloxacin because of the poor solubility of ciprofloxacin at physiological or higher pH, ciprofloxacin formulations were developed at acidic pHs. When these formulations are administered topically to the eye, they can be uncomfortable for some individuals.
  • the present invention is directed to improved topical ophthalmic or otic compositions containing ciprofloxacin and a polystyrene sulfonic acid polymer.
  • the compositions are formulated such that the solubility of ciprofloxacin at a higher pH is increased by the use of an ionic polymer (namely, polystyrene sulfonic acid polymer) which binds with the ciprofloxacin.
  • the binding between the polymer and the ciprofloxacin additionally provides for both initial and continual comfort upon instillation in the eye, as there is less free drug to irritate the tissues of the eye.
  • Another added benefit to the compositions of the present invention is that there is sustained release of the ciprofloxacin.
  • compositions of the present invention contain a synergistic combination of ciprofloxacin having antibacterial activity and a polystyrene sulfonic acid polymer, preferably at physiological or near- physiological pH. These compositions are especially useful in the eye, as the compositions are comfortable upon topical administration to the eye and provide for sustained release of ciprofloxacin.
  • polystyrene sulfonic acid polymers (and their salts) which are used in the formulations of the present invention have the following formula:
  • R H or CH ⁇
  • X an integer such that the molecular weight of the polystyrene sulfonic acid polymer may vary from about 10,000 to 1.6 million.
  • R is H and the molecular weight is between about 500,000 and 1,000,000, preferably about 600,000.
  • the polystyrene sulfonic acid polymers are used in the formulas of the present invention at a concentration less than about 8.0 percent by weight (wt%), preferably less than about 5.0 wt%.
  • Ciprofloxacin Ciprofloxacin, its preparation and use as an antimicrobial, are disclosed in U.S. Patent No. 4,670,444 (Grohe, et al.). The entire contents of that patent is incorporated herein by reference.
  • Ciprofloxacin has the following structure:
  • the chemical name for ciprofloxacin is l-cyclopropyl-6-fluoro-l,4-dihydro-4-oxo-7- (l-piperazinyl)-3-quinoline carboxylic acid.
  • the ciprofloxacin concentration in the formulations is less than or about 1.0 wt% of the total composition, preferably between about 0.1 wt% and 0.75 wt%.
  • the most preferred concentration is between about 0.2 and 0.4 wt%.
  • compositions of the present invention are prepared by combining the ciprofloxacin with the polystyrene sulfonic acid polymer in aqueous media and adjusting the pH, if necessary.
  • the compositions of the present invention may also include one or more ingredients conventionally found in ophthalmic or otic formulations, such as preservatives (e.g., benzalkonium chloride or thimerosal), viscosity-imparting agents (e.g., polyvinyl alcohol or hydroxypropylmethyl- cellulose), and toni ⁇ ty agents (e.g., sodium chloride or mannitol).
  • preservatives e.g., benzalkonium chloride or thimerosal
  • viscosity-imparting agents e.g., polyvinyl alcohol or hydroxypropylmethyl- cellulose
  • toni ⁇ ty agents e.g., sodium chloride or mannitol
  • compositions will also normally include buffering agents, such as phosphates and citrates, to maintain the pH within the range of physiological pH (pH between 6.0 and 7.5). Hydrochloric acid or sodium hydroxide will typically be used to adjust the pH of the resultant composition.
  • buffering agents such as phosphates and citrates
  • Hydrochloric acid or sodium hydroxide will typically be used to adjust the pH of the resultant composition.
  • the compositions are useful in treating ophthalmic and otic bacterial infections and are administered one to four times daily according to the discretion of a skilled clinician.
  • Ciprofloxacin HC1 Monohydrate 0.35*
  • Step 13 If batch weight is less than 99% of the weight measured in Step 10, adjust to the weight in Step 10 with Purified Water through the hydrophilic sterilizing filter. Mix to homogeneity (minimum of 15 minutes).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention porte sur des compositions pharmaceutiques aqueuses contenant une combinaison synergique de ciprofloxacine et d'un polymère d'acide polystyrène sulfonique. Ces compositions, qui se présentent sous la forme d'une solution limpide, sont d'une administration commode et sont à libération prolongée. L'invention porte également sur des modes d'emploi de ces compositions.
PCT/US1995/006587 1995-05-24 1995-05-24 Compositions antibacteriennes WO1996037191A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/US1995/006587 WO1996037191A1 (fr) 1995-05-24 1995-05-24 Compositions antibacteriennes
AU27621/95A AU705718B2 (en) 1995-05-24 1995-05-24 Antibacterial compositions
JP52719495A JP2944759B2 (ja) 1995-05-24 1995-05-24 抗菌性組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/006587 WO1996037191A1 (fr) 1995-05-24 1995-05-24 Compositions antibacteriennes

Publications (1)

Publication Number Publication Date
WO1996037191A1 true WO1996037191A1 (fr) 1996-11-28

Family

ID=22249170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/006587 WO1996037191A1 (fr) 1995-05-24 1995-05-24 Compositions antibacteriennes

Country Status (3)

Country Link
JP (1) JP2944759B2 (fr)
AU (1) AU705718B2 (fr)
WO (1) WO1996037191A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066126A2 (fr) * 1999-04-29 2000-11-09 Alza Corporation Composition liposomique pour une retention medicamenteuse amelioree
EP2273989A4 (fr) * 2008-04-07 2013-05-01 Interface Biologics Inc Polythérapie pour le traitement des infections bactériennes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624281B2 (ja) * 2009-04-21 2014-11-12 東亜薬品株式会社 光安定性に優れたキノロン系抗菌薬含有液体製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444A (en) * 1980-09-03 1987-06-02 Bayer Aktiengesellschaft 7-amino-1-cyclopropyl-4-oxo-1, 4-dihydro-quinoline-and naphthyridine-3-carboxylic acids and antibacterial agents containing these compounds
US5104649A (en) * 1988-05-11 1992-04-14 Monsanto Company Surface-functionalized biocidal polymers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3142854A1 (de) * 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-piperazino-chinolin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
CA2064160C (fr) * 1991-03-27 1998-08-11 Paul J. T. Missel Emploi de polysaccharides gelifiants combines a des substrats finement divises a action de vecteur des medicaments, dans des compositions ophthalmiques a usage local

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444A (en) * 1980-09-03 1987-06-02 Bayer Aktiengesellschaft 7-amino-1-cyclopropyl-4-oxo-1, 4-dihydro-quinoline-and naphthyridine-3-carboxylic acids and antibacterial agents containing these compounds
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5104649A (en) * 1988-05-11 1992-04-14 Monsanto Company Surface-functionalized biocidal polymers

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066126A2 (fr) * 1999-04-29 2000-11-09 Alza Corporation Composition liposomique pour une retention medicamenteuse amelioree
WO2000066126A3 (fr) * 1999-04-29 2001-04-05 Alza Corp Composition liposomique pour une retention medicamenteuse amelioree
EP2273989A4 (fr) * 2008-04-07 2013-05-01 Interface Biologics Inc Polythérapie pour le traitement des infections bactériennes

Also Published As

Publication number Publication date
JPH09507679A (ja) 1997-08-05
JP2944759B2 (ja) 1999-09-06
AU2762195A (en) 1996-12-11
AU705718B2 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
KR102044600B1 (ko) 포비돈-요오드를 포함하는 안과용 조성물
TWI231759B (en) Olopatadine formulations for topical administration
CA2295061C (fr) Compositions ophtalmiques stables au stockage contenant du diclofenac et de l'ofloxacine
EP0139535B1 (fr) Compositions pour combattre la toxaemie
EP0604570B1 (fr) Compositions contenant des antibiotiques quinolone et du sulfonate de polystyrol
TWI544934B (zh) 含有氟喹諾酮抗生素藥物之經改良藥學組成物
JPH1160505A (ja) 防腐組成物
JP2003505419A (ja) ケトチフェンを含む眼用組成物
EP0964687A1 (fr) Compositions pharmaceutiques a activite antimicrobienne
EP0235589A2 (fr) Utilisation des quinolones et naphthyridines antibiotiques pour la préparation de médicaments ophthalmiques
JP2022530837A (ja) 眼疾患治療用の組成物および方法
EP0807434B1 (fr) Gouttes oculaires anti-inflammatoires
JPH0363228A (ja) 新生児の眼病に対する抗菌性予防製剤としてのポビドン・よう素製剤と使用方法
EP0233615B1 (fr) Préparation aqueuse et son procédé de fabrication
AU705718B2 (en) Antibacterial compositions
JPH0469342A (ja) 水性医薬製剤
JP2011225605A (ja) 点眼剤
EP2419081B1 (fr) Compositions ophtalmiques aqueuses contenant des agents thérapeutiques anioniques
CA2191597A1 (fr) Compositions antibacteriennes
US20200268763A1 (en) Pharmaceutical formulations for the treatment of dry eye and methods for fabricating and using thereof
JPH02164829A (ja) ヒアルロン酸点眼液
JP4961671B2 (ja) 点眼剤
WO2000001365A1 (fr) Compositions ophtalmiques a liberation prolongee contenant une fluoroquinolone
PL199321B1 (pl) Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
KR100261585B1 (ko) 항염증점안제

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2191597

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase